Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background/aim: Chemokine (C-C motif) ligand 2 (CCL2) influences growth and metastasis and is associated with poor prognosis in various cancers. However, the regulatory mechanism of CCL2 induction by human epidermal growth factor receptor 2 (HER2) is not fully understood in breast cancer. Thus, we investigated how CCL2 expression is regulated in HER2-positive (HER2+) breast cancer.

Materials And Methods: A human cytokine array was performed to investigate the differential expression of cytokines by HER2 overexpression. Quantitative reverse transcription PCR, enzyme-linked immunosorbent assay and western blot were performed to detect the levels of mRNA and protein expression. Cell cycle and proliferation were analyzed by flow cytometry. Cell invasion was analyzed by Boyden chamber assay.

Results: Our results showed that HER2 overexpression augmented CCL2 expression. Epidermal growth factor receptor (EGFR) and Src activities were increased in the HER2-overexpressed breast cancer cells. Interestingly, HER2-induced CCL2 expression could not be down-regulated by trastuzumab, while neratinib or saracatinib led to a decrease in the expression of CCL2 in HER2+ breast cancer cells.

Conclusion: CCL2 expression is regulated through the EGFR/Src-dependent signaling in HER2+ breast cancer.

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.16253DOI Listing

Publication Analysis

Top Keywords

breast cancer
20
ccl2 expression
16
her2+ breast
12
chemokine c-c
8
c-c motif
8
motif ligand
8
cancer cells
8
epidermal growth
8
growth factor
8
factor receptor
8

Similar Publications

Background: With the availability of more advanced and effective treatments, life expectancy has improved among patients with metastatic breast cancer (MBC), but this makes communication with their medical oncologist more complex. Some patients struggle to learn about their therapeutic options and to understand and articulate their preferences. Mobile health (mHealth) apps can enhance patient-provider communication, playing a crucial role in the diagnosis, treatment, quality of life, and outcomes for patients living with MBC.

View Article and Find Full Text PDF

Background: Iron metabolism may influence breast cancer development; however, links between iron-related biomarkers and breast cancer remain inconclusive. Given differences in iron status by menopausal status, we examined associations of ferritin and other iron biomarkers, with breast cancer incidence, stratified by menopausal status, in a Korean screening cohort.

Methods: This cohort study included 140,747 Korean women screened for breast cancer from 2011-2020.

View Article and Find Full Text PDF

Background: Alcohol consumption is a risk factor for certain cancers and is increasing in the United States. We estimated the impact of alcohol consumption on cancer incidence trends in the United States from 2008-2019 across six alcohol-related cancers among men and women.

Methods: Average daily alcohol consumption (ADC) was calculated from the National Health Interview Survey (NHIS, 1998-2009) and adjusted to per capita sales data to account for underreporting alcohol use.

View Article and Find Full Text PDF

Hormonal receptor status and lymph nodes involvement in breast cancer: a retrospective study.

Cell Mol Biol (Noisy-le-grand)

September 2025

Assistant Professor of General Surgery, Department of Surgery, College of Medicine, University of Duhok, Kurdistan Region, Iraq.

Hormonal status and lymphatic invasion are two important prognostic factors among cases of breast cancer. This study aims to assess and evaluate the hormonal receptor status and lymph node involvement among female breast cancer patients in Duhok city, Kurdistan region, Iraq. A retrospective cross-sectional study was conducted, involving 156 diagnosed cases of breast cancer who had undergone surgical treatment and laboratory investigations at Azadi Teaching Hospital and Duhok Private Hospital for 30 months.

View Article and Find Full Text PDF

Metastatic involvement (MB) of the breast from extramammary malignancies is rare, with an incidence of 0.09-1.3% of all breast malignancies.

View Article and Find Full Text PDF